The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).
A retrospecitve analysis of non-randomized moderate-
Read Article
The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.
Many patients do have psoriasis before onset of symptoms. This question can either be explored retrospectively using existing data or
Read Article
Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. The current study of Tillett et al (OP0231) assessed comorbidities and patient characteristics comparing
Read Article
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Read Article
Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e. acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE), and nonspecific LE
Read Article
Links:
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
Read Article
Links:
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Links:
Links:
Links:
Dr. Rachel Tate @uptoTate( View Tweet )
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm
After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations. Here are a few of the highlights that I saw.
Read Article
Eric Dein @ejdein1( View Tweet )
Links:
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Metanalysis (11 RCTs, 19 registries) of Pulm arterial HTN assoc. w/ CTD (w/ 1,267 & 4,008 CTD-PAH pts), showed Investigational Rxs reduced morbidity/mortality by 36%. CTD-PAH survival
Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
A 3rd year medical student started his rotation with me this past week and the rotation was a challenge for us both.
Read Post
